s 
regarding FDA's evaluation of the evidence, which are discussed in 
detail in comments 1 to 4 of this section II.
    (Comment 1) The petitioner commented that it was inappropriate for 
FDA to refer to sucralose-based sugar substitute products by brand 
names in the preamble; specifically in regards to statements about 
specific SPLENDA sugar substitute products not meeting the eligibility 
criteria of Sec.  101.80(c)(2)(iii). The petitioner noted that the 
SPLENDA brand name did not appear in th